Study design criteria for regulatory-based drug control action: Drug discrimination

Area of Science:

• Pharmacology
• Neuroscience
• Drug Safety Evaluation

Background:

• New central nervous system drugs require rigorous safety evaluations, including abuse liability assessment.
• The drug discrimination (DD) assay is a key method for evaluating a drug's abuse potential.
• Compliance with Good Laboratory Practice Guidelines (GLPs) is essential for regulatory acceptance.

Purpose of the Study:

• To outline critical factors in designing and conducting drug discrimination (DD) studies for abuse liability risk assessment.
• To ensure DD study data meets regulatory expectations for drug scheduling recommendations.
• To highlight the importance of methodological rigor in late-stage drug development.

Main Methods:

• Focus on three critical experimental design factors in DD studies: reference drug selection, training dose selection, and route of administration.
• Ensuring study protocols adhere to Good Laboratory Practice Guidelines (GLPs).
• Data generated from these studies inform the US Food and Drug Administration's (FDA) drug scheduling review process.

Main Results:

• The selection of reference drugs, training doses, and routes of administration directly impacts the data's utility for regulatory decision-making.
• Methodological choices determine if the study data adequately addresses the 8 factors for controlled substance scheduling recommendations.
• Adherence to GLPs ensures data integrity and regulatory compliance.

Conclusions:

• Optimizing DD assay methodology is critical for accurate abuse liability assessment of new CNS drugs.
• Errors in study design or execution late in development pose significant economic and programmatic risks.
• Robust DD study data is essential for meeting the Controlled Substances Act requirements and informing FDA scheduling decisions.